Cellular immunotherapy in multiple myeloma: lessons from preclinical models

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• Multiple myeloma (MM) is a hematologic malignancy with high relapse rates despite current therapies.
• Cellular immunotherapy shows promise in various cancers, including MM, and is advancing into clinical trials.
• Effective therapeutic strategies for MM are urgently needed.

Purpose of the Study:

• To review immune cell alterations in patients with multiple myeloma.
• To discuss cell-based immunotherapies investigated for multiple myeloma treatment.
• To highlight the role of murine models in advancing MM immunotherapy.

Main Methods:

• Literature review of immune cell changes in multiple myeloma.
• Review of preclinical and clinical studies on cell-based immunotherapies for multiple myeloma.
• Focus on the application and findings from murine models of multiple myeloma.

Main Results:

• Multiple myeloma is associated with significant immune dysregulation.
• Various cellular immunotherapies, including CAR-T cells and NK cells, are being explored for MM.
• Murine models provide valuable insights into immunotherapy efficacy and mechanisms in MM.

Conclusions:

• Cellular immunotherapy represents a promising avenue for overcoming treatment resistance in multiple myeloma.
• Further research utilizing murine models is crucial for optimizing cell-based therapies for MM.
• Understanding immune changes in MM is key to developing more effective immunotherapeutic strategies.